Secondary Myelofibrosis Recruiting Phase 2 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0030964 (Secondary Myelofibrosis)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04370301Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisTreatment